Trial Profile
Safety, efficacy and tolerability of Ribavirin-free, Sofosbuvir-Based regimens for the treatments of chronic hepatitis C in patients with End-Stage Renal Disease.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 11 May 2016 New trial record
- 17 Apr 2016 Interim results (n=33) presented at The International Liver Congress™ 2016